Cardiometabolic Health Explained Using GLP-1 Therapy

“

Abstract

In this educational post, I will guide you through a modern, multifaceted approach to managing type 2 diabetes and related chronic conditions that goes far beyond simple glucose control. We will explore why a comprehensive strategy focusing on cardiovascular and renal risk reduction is now the standard of care. I will introduce you to the revolutionary class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists, detailing their powerful mechanisms of action, diverse benefits, and specific roles in patient care. We will examine the latest evidence from landmark clinical trials such as LEADER, SUSTAIN-6, and SELECT, differentiating among GLP-1 agents based on their efficacy in lowering A1C, promoting weight loss, and providing cardiovascular and kidney protection. Using clinical case studies, I’ll illustrate the practical application of these agents, discuss how to integrate them into treatment plans, and provide guidance on switching between therapies. We will also explore the exciting investigational uses for these drugs in conditions like MASH, neurodegenerative disorders, and PCOS. Finally, I will explain how integrative chiropractic care complements this biomedical approach, supporting patients’ overall health and well-being on their journey to improved outcomes.

Hello, and thank you for joining me. I’m Dr. Alexander Jimenez, and with my credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), board-certified Family Nurse Practitioner (FNP-BC), and certifications in functional and integrative medicine (CFMP, IFMCP), I am dedicated to bringing you the latest findings from leading researchers in the field, presented through the lens of modern, evidence-based methods. I strive to bridge conventional and complementary approaches to health.

In my practice, I’ve seen firsthand the evolution of how we manage chronic conditions. Today, I want to share a significant shift in the management of type 2 diabetes and cardiometabolic health—a move away from a purely glucose-centric model to a comprehensive, risk-reduction strategy. We’ll delve into a class of medications that are central to this new paradigm: GLP-1 receptor agonists. Originally developed for type 2 diabetes, their benefits have proven to be far more extensive, marking a monumental leap forward in how we approach chronic disease.

A Paradigm Shift: Understanding the Broader Risks of Type 2 Diabetes

For many years, the primary goal in diabetes management was to lower blood sugar and A1C levels. While this remains crucial, we now have a much deeper understanding of the broader implications of this disease. Leading research has unequivocally shown that patients with type 2 diabetes face a profoundly elevated risk for developing atherosclerotic cardiovascular disease (ASCVD), which includes coronary heart disease, stroke, and peripheral arterial disease.

In fact, ASCVD is the leading cause of death for individuals with type 2 diabetes. Consider these stark statistics:

• Over 70% of elderly individuals with diabetes are likely to succumb to heart disease or stroke.
• The risk of death following a heart attack (myocardial infarction or MI) is significantly higher for people with diabetes.
• The long-term prognosis for those with both diabetes and coronary artery disease is poor, even when their diabetes is considered “well-controlled” by traditional glucose metrics.

These sobering facts have forced a fundamental change in our approach. We can no longer treat diabetes in a silo. The era of viewing GLP-1 receptor agonists as just “diabetes drugs” is over. We must now recognize their central role in managing the interconnected cardio-renal-metabolic triad. These systems have bidirectional relationships; dysfunction in one often causes or worsens dysfunction in the others. GLP-1s, along with SGLT2 inhibitors, are uniquely positioned to address all three facets simultaneously.

The Pillars of Modern Diabetes Management

Today, the standard of care calls for a multifaceted, collaborative management plan. The emphasis has shifted from a singular focus on glucose to a holistic strategy to reduce a patient’s overall cardiovascular and metabolic risk.

This comprehensive approach is endorsed by all major international guideline bodies, including the American College of Cardiology (ACC), the American Heart Association (AHA), the American Diabetes Association (ADA), and Kidney Disease: Improving Global Outcomes (KDIGO). They all agree that effective management must include:

• Aggressive Blood Pressure Control: Managing hypertension is critical to protecting the heart, brain, and kidneys.
• Lipid Management: Controlling cholesterol levels helps prevent plaque buildup in arteries.
• Glucose Regulation: Maintaining stable blood sugar levels remains a cornerstone of care.
• Weight Management: Achieving and maintaining a healthy weight reduces strain on the entire metabolic system.
• Lifestyle Optimization: This includes regular physical exercise and smoking cessation, which are non-negotiable for risk reduction.

The American Diabetes Association visualizes this as the “pillars of management,” with lifestyle management and diabetes education forming the foundation upon which all other interventions are built.

Unlocking the Power of GLP-1 Receptor Agonists

To understand how these medications work, we must first understand the incretin effect. This is a natural physiological process. When we eat, specialized cells in our intestines (called L-cells) release hormones, most notably GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). These hormones signal the pancreas to release insulin in a glucose-dependent manner. This means they stimulate insulin secretion only when blood sugar levels are rising after a meal, a beautifully intelligent and safe mechanism that prepares the body to use the glucose from food efficiently.

A key pathophysiological feature of type 2 diabetes is that this natural incretin effect is severely blunted. Individuals with type 2 diabetes produce insufficient amounts of their native GLP-1 hormone. This leads to low insulin secretion after a meal and unchecked glucagon secretion, a hormone that signals the liver to release stored glucose. GLP-1 receptor agonists are synthetic versions of our natural GLP-1 hormone, designed to be more resistant to breakdown and to restore this crucial signaling pathway effectively.

The Multifaceted Mechanisms of Action

The power of GLP-1 agonists lies in their ability to act on multiple organs and systems simultaneously:

• In the Gastrointestinal (GI) Tract: These drugs significantly slow down gastric emptying, meaning food stays in the stomach longer. This is a major contributor to the feeling of fullness, or satiety, helping reduce food intake and drive weight loss. It is also the source of common side effects like nausea.
• In the Brain, GLP-1 agonists can cross the blood-brain barrier and act directly on the hypothalamus, the brain’s appetite control center. This central action decreases appetite and enhances satiety.
• In the pancreas, they promote glucose-dependent insulin secretion from pancreatic beta cells while simultaneously lowering glucagon secretion, which reduces the liver’s excessive production of glucose. This dual action is a cornerstone of their glycemic-lowering effect.

This comprehensive mechanism aligns beautifully with the “Ominous Octet” model proposed by Dr. Ralph DeFronzo, which outlines the eight core pathophysiological defects in type 2 diabetes. GLP-1 agonists effectively address six of these eight defects, making them a remarkably comprehensive therapy (DeFronzo, 2009).

Clinical Case Study: Naomi’s Journey

To illustrate these concepts, let’s consider a patient I might see in my clinic, whom we’ll call Naomi.

Naomi is a 66-year-old female who has been living with type 2 diabetes for over 12 years. Her clinical picture is complex:

• A1C: Her last A1C was 8.3%, well above the target of less than 7%.
• Comorbidities: She has hypertension, hyperlipidemia (HLD), and proteinuria (protein in the urine), a sign of kidney stress.
• Medications: She is on metformin 1000 mg twice daily, a statin, an ARB, and an SGLT2 inhibitor.
• Insulin Use: She takes 66 units of Degludec (a long-acting basal insulin) daily.
• Blood Glucose Readings: Despite her high insulin dose, her fasting glucose is 140-160 mg/dL, and postprandial (after-meal) glucose is 160-170 mg/dL.
• Physical Metrics: She is 5’9″, weighs 220 pounds, with a BMI of 32.5 (obese range).

My clinical observation reveals a common scenario: she is “over-basalized”. This means she is on a very high dose of basal insulin (over 50 units for her 100 kg weight), yet her glucose is not at goal. The traditional next step might be adding mealtime insulin. However, a more modern, strategic approach is to consider a GLP-1 receptor agonist first. The goal would be to target her after-meal glucose spikes, promote weight loss (unlike insulin, which often causes weight gain), and provide robust A1C reduction, all while simplifying her regimen.

The Evolution of GLP-1 Therapies: A Journey of Increasing Efficacy

The story of GLP-1 agonists is one of continuous innovation. The timeline shows a clear progression in their ability not only to control blood sugar but also to achieve significant weight loss.

Medication (Brand Name)	Primary Indication(s)	Key FDA-Labeled Benefits	Average A1C Reduction	Average Weight Loss
Exenatide (Byetta)	Type 2 Diabetes	None specified for CV/Kidney	~0.9%	~2.9 kg (6.4 lbs)
Liraglutide (Victoza)	Type 2 Diabetes	MACE Reduction, Nephropathy Protection	~1.1%	~2.7 kg (5.5 lbs)
Lixisenatide (Adlyxin)	Type 2 Diabetes	None specified for CV/Kidney	Variable	~2.6 kg (5.7 lbs)
Dulaglutide (Trulicity)	Type 2 Diabetes	MACE Reduction, Nephropathy Protection	Variable, dose-dependent	~4.6 kg (10.1 lbs)
Semaglutide (Ozempic/Rybelsus/Wegovy)	T2D, Weight Loss	MACE Reduction, Nephropathy Protection	1.8-2.1%	~6.4 kg (14.1 lbs)
Tirzepatide (Mounjaro/Zepbound)	T2D, Weight Loss, OSA	MACE Reduction	~2.3%	~11.2 kg (24.7 lbs)

• A note on Tirzepatide: This agent is a “twincretin,” or dual-agonist, acting on both GLP-1 and GIP. This dual action has shown even greater efficacy in reducing A1C and promoting weight loss. It also recently gained an FDA indication for Obstructive Sleep Apnea (OSA).

For a patient like Naomi with multiple risk factors, choosing an agent with proven reductions in MACE (Major Adverse Cardiovascular Events) and nephropathy (kidney disease) protection is essential.

Landmark Trials: Proving Cardiovascular and Renal Benefits

Perhaps the most groundbreaking discovery about GLP-1 agonists was their ability to provide profound cardiovascular and renal protection. This journey began after 2008, when the FDA mandated that all new diabetes drugs undergo large-scale Cardiovascular Outcomes Trials (CVOTs). What researchers found was not just safety, but unexpected and robust benefits.

Key CVOTs for GLP-1 Agonists

• REWIND Trial (Dulaglutide): Showed a 12% reduction in MACE, demonstrating a primary prevention benefit.
• LEADER Trial (Liraglutide): Found a 13% risk reduction in MACE in a high-risk population.
• SUSTAIN-6 Trial (Semaglutide): Demonstrated an impressive 26% reduction in MACE.
• PIONEER 6 Trial (Oral Semaglutide): The oral formulation also proved its cardiovascular safety.

Expanding the Indications: Beyond Diabetes

More recent trials have expanded the use of these drugs to patients without diabetes.

• STEP-HFpEF Trial: Investigated semaglutide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). The medication led to stunning improvements in heart failure symptoms and physical limitations.
• SELECT Trial: This landmark study involved over 17,000 overweight or obese patients with pre-existing cardiovascular disease but did not have diabetes. Semaglutide 2.4 mg demonstrated a 20% reduction in the risk of MACE.

These trials were game-changers, proving that the cardiovascular benefits are independent of glucose-lowering effects and firmly establishing these drugs as critical therapies for cardiovascular risk reduction in a broader population. This is why I, and many of my colleagues, now share them with our cardiology and nephrology partners.

---

Balancing Body and Metabolism- Video

---

Navigating Patient Care: Switching Between GLP-1 Receptor Agonists

In my clinical practice, I often encounter patients who are not achieving their goals on their current GLP-1 agent. This was the situation with a patient I’ll call Tammy, who was on Trulicity (dulaglutide) 1.5 mg but wasn’t experiencing the necessary satiety for her weight loss journey. Given her preference to switch to a more potent agent, such as Ozempic or Mounjaro, we developed a transition plan.

A Guideline for Switching Therapies

Switching between these medications requires a careful, evidence-informed approach.

• Switching from Trulicity (dulaglutide) to Ozempic (semaglutide): After discontinuing Trulicity and waiting a full week, a conservative approach is to start semaglutide at the 0.5 mg weekly dose, not the initial 0.25 mg dose. This helps acclimate the body and reduces GI side effects. We can then titrate up to 1.0 mg after a month if needed.
• Switching from Trulicity (dulaglutide) to Mounjaro (tirzepatide): Following the same one-week washout, I recommend starting tirzepatide at the 5 mg weekly dose. Tirzepatide offers a wide range of doses, and the goal is to find the optimal effective dose for each individual—one that provides sustained satiety without undue side effects.

Beyond Diabetes and Obesity: The Investigational Frontier of GLP-1s

The therapeutic potential of GLP-1 receptor agonists extends far beyond their initial indications.

• Metabolically Dysfunctional-Associated Steatotic Hepatitis (MASH): The profound weight loss from agents like semaglutide reduces fat accumulation in the liver, with Novo Nordisk reporting highly positive trial data.
• Neuropsychiatric and Neuroprotective Effects: GLP-1s that cross the blood-brain barrier have the potential to slow dementia progression, improve Parkinson’s symptoms, and even reduce seizures.
• Cravings and Compulsive Behaviors: A fascinating report from my patients is a dramatic reduction in cravings for food, alcohol, and nicotine, suggesting these drugs modulate the brain’s reward pathways.
• PCOS, Fertility, and Respiratory Health: GLP-1s are showing promise for Polycystic Ovary Syndrome (PCOS) and infertility by improving insulin resistance. The media buzz about “Ozempic babies” highlights this effect.
• Autoimmune Diabetes (LADA) and Type 1 Diabetes: An exciting off-label use is in Latent Autoimmune Diabetes in Adults (LADA), where early use may preserve pancreatic function.

The Role of Integrative Chiropractic Care

While these advanced pharmaceuticals are transforming medical management, a holistic approach yields the best results. This is where integrative chiropractic care plays a vital and synergistic role.

• Neuromusculoskeletal Health and Structural Realignment: Significant weight loss alters a person’s center of gravity and the mechanical stresses on the body. Chiropractic adjustments are crucial for helping the body adapt, ensuring proper spinal alignment, joint mobility, and alleviating pain in the back, hips, or knees. By maintaining musculoskeletal integrity, we empower patients to engage in the regular physical activity critical for managing blood sugar and preserving muscle mass.
• Functional Nutrition and Lifestyle Coaching: A CFMP and IFMCP-certified provider goes beyond generic advice. We help patients implement personalized anti-inflammatory diets that complement GLP-1 agents, improve insulin sensitivity, and reduce systemic inflammation. We develop tailored exercise programs that combine cardio with resistance training to preserve lean muscle mass during weight loss.
• Stress Management and Autonomic Nervous System Regulation: Chronic stress elevates cortisol, which raises blood sugar. Chiropractic care, particularly focused on the upper cervical spine, can influence the autonomic nervous system, helping to shift the body from a “fight-or-flight” (sympathetic) state to a “rest-and-digest” (parasympathetic) state. This regulation can help lower blood pressure and mitigate the physiological effects of stress.

By weaving together cutting-edge science with the time-tested principles of chiropractic and functional medicine, we create a comprehensive treatment plan. We are not just managing a disease; we are actively rebuilding health from the ground up.

Safety, Side Effects, and Practical Guidance

While the benefits are substantial, it’s essential to be aware of the safety profile. The most common issues are gastrointestinal, stemming from slowed gastric emptying.

Common Side Effects:

• Nausea: Most frequent, but generally improves over time.
• Constipation or Diarrhea: Varies by person.
• Mild Abdominal Pain.

The key to management is to start low and titrate slowly. Crucially, patient education is paramount. I always counsel my patients:

“When you start this medication, you cannot eat the way you used to. Avoid ‘carb-loading’ and steer clear of large, high-fat meals. A large burger, fries, and a milkshake is a recipe for significant nausea and vomiting.”

Important Safety Considerations:

• Gallbladder Events: Rapid weight loss of any kind can increase the risk of gallstones.
• Pancreatitis: Rare, but patients should seek immediate care for severe, persistent abdominal pain.
• Pre-Surgical Guidelines: Anesthesiology societies recommend holding weekly GLP-1 agonists for at least one week before elective surgery due to delayed gastric emptying.
• Black Box Warning (Thyroid C-Cell Tumors): In rodent studies, these drugs were associated with thyroid C-cell tumors. They are contraindicated in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

The Future on the Horizon

The pipeline for new metabolic drugs is robust. Eli Lilly’s oral GLP-1, or forglipron, may be next to market. We are also eagerly awaiting novel triple-agonist drugs and co-agonists, such as Novo Nordisk’s amylin/GLP-1 combination, which promise even greater efficacy and are likely to arrive in 2025 or early 2026. While these medications are safe and effective, their high cost remains a barrier. We are hopeful that with increased competition, these life-changing therapies will become more affordable.

This is a pivotal moment in medicine. By combining these advanced pharmacological tools with a holistic, integrative approach that includes chiropractic care, nutritional science, and lifestyle medicine, we help our patients reach a level of health and well-being they may not have thought possible.

References

• American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S158–S178. doi.org/10.2337/dc24-S009
• Collins, L., & Costello, R. A. (2023). Glucagon-like Peptide-1 Receptor Agonists. In StatPearls. StatPearls Publishing. www.ncbi.nlm.nih.gov/books/NBK551568/
• DeFronzo, R. A. (2009). From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 58(4), 773–795. doi.org/10.2337/db09-9028
• Drucker, D. J. (2022). GLP-1 physiology, pathophysiology, and pharmacology. Cell Metabolism, 34(5), 646–663. doi.org/10.1016/j.cmet.2022.04.001
• Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Ryden, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., & Avezum, A. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomized placebo-controlled trial. The Lancet, 394(10193), 121–130. doi.org/10.1016/S0140-6736(19)31149-3
• Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Hovingh, G. K., Gjerp, F. W., Jodar, E., Pipilis, A., Polonsky, W. H., Tarp-Johansen, M. J., & Buse, J. B. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 381(9), 841–851. doi.org/10.1056/NEJMoa1901118
• Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Nielsen, M. L., Petrie, M. C., Rasmussen, S., Sjöstrand, M., & Shah, S. J. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, 389(12), 1069–1084. doi.org/10.1056/NEJMoa2306963
• Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, E. A., Story, U., & Tarp-Johansen, M. J. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. doi.org/10.1056/NEJMoa2307563
• Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Saugstrup, S., Wolden, M. L., Buse, J. B., & SUSTAIN-6 Investigators. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844. doi.org/10.1056/NEJMoa1607141
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., Buse, J. B., & LEADER Steering Committee on behalf of the LEADER Trial Investigators. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322. doi.org/10.1056/NEJMoa1603827
• Nauck, M. A., & D’Alessio, D. A. (2022). The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 399(10342), 2247–2261. doi.org/10.1016/S0140-6736(22)00344-7
• The Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1–S127. doi.org/10.1016/j.kint.2022.06.008
• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. doi.org/10.1056/NEJMoa2032183

SEO Tags: GLP-1 agonists, GLP-1 receptor agonists, type 2 diabetes, cardiovascular risk reduction, Ozempic, Mounjaro, Wegovy, Trulicity, integrative chiropractic care, functional medicine, Dr. Alexander Jimenez, weight loss, A1C, diabetes management, incretin effect, ASCVD, kidney protection, evidence-based medicine, lifestyle management, postprandial glucose, semaglutide, tirzepatide, cardiovascular disease, heart failure, SUSTAIN-6, SELECT trial, STEP-HFpEF, cardiovascular outcomes, renal protection, obesity treatment, MASH, neuroprotective effects, satiety, patient-centered care, chiropractic adjustments, subluxation, biomechanics, LADA, PCOS, cardio-renal-metabolic